Shots: The MAA submission follows the results of P-II DELPHI study, DELPHI-Extension study, P-III DELOS (1-5) study and SYROS study. The collective studies result demonstrated that Puldysa (idebenone) is showing […]readmore
Tags : Santhera
Shots: Santhera to receive $49.5M upfront, ~$54.5M as milestones, making the total deal value ~104M. Chiesi to get an exclusive WW rights to develop & commercialize Raxone for LHON and […]readmore
Shots: Santhera enters into a collaboration with Biozentrum, University of Basel to explore the feasibility of the gene therapy by standard viral vectors for LAMA2 MD or MDC1A, co-financed by […]readmore
Shots: The P-III DELOS study involves assessing of Idebenone (900 mg/day) vs PBO in 64 patients with Duchenne muscular dystrophy (DMD) for 52wks. & P-II DELPHI study with 2-year extension […]readmore
Shots: The P-III DELOS trial involves assessing of idebenone (900mg/day) vs PBO in 64 patients with DML for 52 wks. P-III DELOS study results: 50% reduction in annual rates of […]readmore